Table 1.

Comparison of topical MMC, 5FU and IFN.

Medication	Mechanism of action	Recommended Regimen	Adverse events
Mitomycin-C	Alkylating agent Cell cycle independent effects.	MMC 0.04%, QID Cycle: one week on, one week off Duration: 3 cycles	Limbal stem cell deficiency Punctal stenosis Conjunctivitis Lid toxicity Recurrent corneal erosion Punctate keratopathy
5-Fluorouracil	Pyrimidine analogue Cell cycle dependent effects.	5FU 1%, QID Cycle: one week on and three weeks off, OR One month on and one month off. Duration: continue for one cycle after resolution.	Punctate epithelial erosions Corneal ulceration Lid toxicity Keratoconjunctivitis
Interferon-α2b	Anti-viral, cytostatic, pro-apoptotic, anti-angiogenic, immunomodulatory.	IFN 1 million IU/ml QID for 1–3 months after resolution. IFN 3 million IU/0.5 ml, perilesional injection weekly until resolution.	Follicular conjunctivitis Corneal erosion Corneal ulcer Epithelial microcysts Flu-like symptoms (with perilesional injections)

^aQID = four times a day.